Loxo Oncology, Inc. (NASDAQ:LOXO) insider Naarden Jacob Van sold 1,541 shares of the company’s stock in a transaction dated Tuesday, October 31st. The shares were sold at an average price of $86.52, for a total transaction of $133,327.32. Following the transaction, the insider now owns 1,541 shares in the company, valued at approximately $133,327.32. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Naarden Jacob Van also recently made the following trade(s):

  • On Monday, September 18th, Naarden Jacob Van sold 1,541 shares of Loxo Oncology stock. The shares were sold at an average price of $89.20, for a total transaction of $137,457.20.
  • On Tuesday, September 19th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The shares were sold at an average price of $89.00, for a total transaction of $274,298.00.
  • On Monday, August 14th, Naarden Jacob Van sold 1,541 shares of Loxo Oncology stock. The shares were sold at an average price of $73.73, for a total transaction of $113,617.93.
  • On Tuesday, August 15th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The shares were sold at an average price of $73.57, for a total transaction of $226,742.74.

Loxo Oncology (NASDAQ:LOXO) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.99) by ($0.15). During the same quarter in the prior year, the business earned ($0.77) earnings per share.

ILLEGAL ACTIVITY NOTICE: “Loxo Oncology, Inc. (LOXO) Insider Naarden Jacob Van Sells 1,541 Shares” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.watchlistnews.com/loxo-oncology-inc-loxo-insider-naarden-jacob-van-sells-1541-shares/1673765.html.

LOXO has been the topic of several recent research reports. Citigroup Inc. reiterated a “buy” rating and issued a $112.00 price objective (up previously from $86.00) on shares of Loxo Oncology in a research note on Friday, October 20th. Morgan Stanley reiterated an “overweight” rating and issued a $103.00 price objective (up previously from $95.00) on shares of Loxo Oncology in a research note on Friday, October 6th. BTIG Research reiterated a “buy” rating and issued a $102.00 price objective (up previously from $75.00) on shares of Loxo Oncology in a research note on Friday, September 29th. Cowen and Company reiterated a “buy” rating on shares of Loxo Oncology in a research note on Thursday, September 28th. Finally, JMP Securities cut shares of Loxo Oncology from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $83.12 to $17.14 in a research note on Tuesday, August 29th. They noted that the move was a valuation call. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $80.02.

A number of large investors have recently made changes to their positions in LOXO. Lord Abbett & CO. LLC lifted its holdings in Loxo Oncology by 372.0% in the second quarter. Lord Abbett & CO. LLC now owns 739,540 shares of the biopharmaceutical company’s stock valued at $59,304,000 after acquiring an additional 582,862 shares during the period. FMR LLC raised its stake in shares of Loxo Oncology by 12.1% during the 2nd quarter. FMR LLC now owns 4,394,827 shares of the biopharmaceutical company’s stock worth $352,420,000 after buying an additional 472,814 shares during the period. Marshall Wace North America L.P. acquired a new position in shares of Loxo Oncology during the 2nd quarter worth approximately $33,347,000. State Street Corp raised its stake in shares of Loxo Oncology by 155.2% during the 1st quarter. State Street Corp now owns 547,017 shares of the biopharmaceutical company’s stock worth $23,019,000 after buying an additional 332,696 shares during the period. Finally, Alliancebernstein L.P. raised its stake in shares of Loxo Oncology by 50.2% during the 2nd quarter. Alliancebernstein L.P. now owns 936,790 shares of the biopharmaceutical company’s stock worth $75,121,000 after buying an additional 312,988 shares during the period.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.